Philips

Key Findings

• Economic: Philips maintains controlled Israeli subsidiaries and an active medical-device establishment in Haifa. Its documented nexus includes manufacturing, research and development, acquisitions, distribution and participation in Israeli public innovation programmes.^{1, 2, 3}
• Political: Philips was a silver sponsor of MIXiii Health-Tech.IL 2025, an industry-organised conference involving Israeli public institutions. Its appearance in the 2026 event catalogue establishes a further commercial association; the financial and contractual continuity of sponsorship remains unresolved.^{4, 5, 6, 7}
• Political: A March 2026 Israeli government notice proposed purchasing a Philips scanner for donation to a Hungarian children’s hospital, expressly describing humanitarian and public-diplomacy objectives. The notice does not establish execution, delivery or Philips’ endorsement of those objectives.⁸
• Not found: No public evidence identified in the supplied audits of Philips supplying Israeli forces with weapons, military-specific equipment, surveillance, offensive cyber or targeting systems. Documented US and UK military healthcare contracts establish geographically separate relationships.^{9, 10, 11}

Target Profile

Executive Summary

Philips’ documented Israel nexus is principally an operating healthcare business. Its 2025 subsidiary schedule lists five Israeli entities, while a 2026 FDA registration identifies an active Haifa medical-device establishment owned or operated by Philips Medical Systems International B.V. in the Netherlands. Corporate research materials describe medical imaging, cardiac navigation, oncology informatics and enterprise imaging development across several Israeli locations. The Israel Innovation Authority records research-programme participation in 2023 and 2025.^{1, 2, 3, 17}

The strongest economic evidence concerns controlled operations, manufacturing and acquisitions. Philips announced a EUR 250 million upfront acquisition agreement for EPD Solutions in 2018, with additional contingent consideration, and acquired DiA Imaging Analysis in 2023. Israeli public procurement notices additionally identify proposed purchases or servicing arrangements involving Philips subsidiaries, branded equipment and distribution partner Medtechnica. These notices establish proposed commercial parameters; they do not independently establish signed contracts, payments, delivery or performance.^{20, 21, 22, 23, 24, 25, 26}

The political record concerns institutional association and promotion rather than verified military advocacy. Philips’ 2025 MIXiii silver sponsorship placed its brand within an industry initiative promoting Israeli health technology in cooperation with public institutions. A separate 2026 catalogue includes Philips, but equivalent sponsorship terms are unverified. Israel’s proposed March 2026 purchase of a Philips scanner for a Hungarian hospital expressly combined humanitarian assistance with showcasing Israeli innovation; those objectives belong to the ministry’s notice and cannot automatically be attributed to Philips.^{8, 4, 5, 6, 7}

The principal counterweight is the civilian character of the documented activity. No public evidence identified in the audits establishes Israeli military supply, weapons integration, military surveillance, offensive cyber, settlement facilities or settlement-specific procurement. Clinical AI integration with Israeli company Ibex is documented, but Israeli hosting of patient information, unrestricted Israeli access and deployment-specific model-training flows remain unresolved. Philips also lists Palestinian healthcare distribution channels.^{17, 9, 10, 11, 18, 19, 27, 28, 29}

The fixed, human-vetted V6.6 result is BRS 792, Tier B (Severe Complicity), with Economic 9.00, Political 7.50, and Military and Digital both 0.00. This is the corpus’s scoring classification. It does not convert civilian healthcare activity into military activity, establish a settlement nexus, or resolve the contractual and technical uncertainties recorded below.

Timeline of Relevant Events

Corporate Overview

The Dutch parent’s 2025 SEC schedule lists Dia Imaging Analysis Ltd., EPD Research Ltd., LifeWatch Technologies, Ltd., Philips Electronics (Israel) Ltd. and Philips Medical Systems Technologies Ltd. The filing states that listed subsidiaries are directly or indirectly 100%-owned unless another percentage is specified. The same five entities appear in the 2024 schedule. These disclosures establish group ownership, without supplying a complete immediate-parent chain for each entity.^{2, 37}

For the Haifa establishment, the FDA specifically identifies Philips Medical Systems International B.V. as owner/operator. Philips’ research directory separately identifies CT/PET-CT work in Haifa, oncology informatics in Haifa and Petach Tikva, KODEX-EPD in Caesarea, Volcano software development in Netanya and Algotec/Carestream enterprise imaging in Ra’anana. These operational descriptions should not be treated as proof that every named activity is a separate current legal subsidiary.^{1, 17}

Philips Electronics (Israel) Ltd. and Medtechnica are identified commercial channels. Medtechnica is a business partner, not established by these records as a Philips-owned subsidiary. The regional directory also lists Palestinian distributors in Ramallah/Al-Bireh. Its Jerusalem entry for Arcomed does not independently resolve whether the premises are in occupied East Jerusalem or establish settlement sales.^{18, 38, 29}

Exor’s minority shareholding and board nomination rights establish investment and governance influence, not everyday operational control. Its separate Israeli venture investments require distinct attribution. For example, Exor Ventures participated in PhaseV financing in 2025; that is not evidence that Philips made the investment or directed the portfolio company.^{14, 35, 39}

Domain Summaries

Military: Military

Mechanism of Involvement

No public evidence identified of an awarded Philips contract with the Israeli Ministry of Defence, IDF, prison service or border police. The identified Israeli procurement records concern civilian medical institutions. The Rambam and Sourasky publications are proposed engagements, not independently verified awards or completed servicing.^{23, 24}

The audits nevertheless establish military healthcare activity elsewhere. Philips North America received a February 2025 US Defense Health Agency award for Lumify development, while Philips Electronics UK received a March 2026 award for MRI maintenance at the Defence Medical Rehabilitation Centre, Stanford Hall.^{10, 11}

The US device registry also identifies a Lumify DoD configuration whose only customer is the US Department of Defense. This establishes a military-specific product configuration; it does not establish its sale to Israel.⁹

Counter-Arguments and Evidence Limits

The strongest defence is geographic and functional: documented military relationships concern US and UK medical care, while the Israeli evidence concerns civilian healthcare. Neither relationship can substitute for evidence of Israeli military end-use. Medical equipment’s portability or military adaptability does not establish that a particular Israeli customer received a military variant.^{9, 10, 11, 23, 24}

No public evidence identified in the military audit of Philips supplying Israeli weapons, munitions, targeting software, defence-prime components, military logistics or occupied-territory military installations. Philips’ described Israeli engineering work concerns clinical imaging and healthcare technology. The absence finding is bounded by the audit’s reviewed record, rather than a guarantee concerning undisclosed transactions.¹⁷

Named Entities and Evidence Map

Digital: Digital

Mechanism of Involvement

Philips’ Israeli-origin clinical technology relationships are substantial but medically defined. The Ibex collaboration began in 2021 and was expanded in March 2025 to integrate AI applications for prostate, breast and gastric cancer diagnostics. Philips described automatic transfer of digital slides to Ibex applications for analysis. Its DiA partnership likewise concerned automated clinical ultrasound measurements.^{19, 31, 30}

Ibex’s February 2026 Data Protection Addendum identifies Ibex as processor and customers as controllers. It permits processing of pseudonymized medical information for service delivery and specified support, enhancement and improvement activities. Its sub-processor register identifies AWS and states that processing country follows customer choice. These establish contractual processing responsibilities, not the location or access arrangements of each Philips deployment.^{27, 28}

The March 2026 Philips cloud announcement identifies AWS infrastructure and Ibex AI interoperability, but expressly qualifies the announced offering and interoperability as works in progress. It therefore cannot establish production deployment of that architecture.³³

Counter-Arguments and Evidence Limits

The strongest defence is the clinical purpose and unresolved deployment geography. No public evidence identified of Philips providing Israeli military surveillance, offensive cyber, autonomous targeting or Project Nimbus services. The documented AI applications concern cancer diagnosis and ultrasound analysis.^{19, 31, 30}

The DPA requires processing under customer instructions and describes deletion, transfer safeguards and encryption. Those provisions do not independently verify compliance, but they qualify claims of unrestricted access. The audit did not establish routine transfer of identifiable slides to Israel, exclusive Israeli infrastructure control or customer-authorised model training in Israeli repositories. Ibex’s website privacy policy excludes commercial-product processing from its scope and cannot resolve those questions.^{27, 28, 40}

The fixed Digital 0.00 therefore coexists with documented Israeli clinical software relationships. The score must not be read as an assertion that no digital relationship exists, nor should the relationships be recast as verified surveillance or military technology.

Named Entities and Evidence Map

Economic: Economic

Mechanism of Involvement

The economic nexus rests on controlled operations rather than brand availability alone. The 2025 subsidiary filing, active 2026 FDA establishment and continuing research descriptions establish an ongoing corporate and production presence. The Innovation Authority identifies approximately 1,300 employees for Philips Medical Systems Technologies, but the figure’s reference date is unresolved and it is not a verified current headcount for all Philips personnel in Israel.^{1, 2, 3, 17}

Acquisitions add documented capital commitments. The 2018 EPD agreement specified EUR 250 million upfront and milestone-dependent payments, with an anticipated contingent-consideration provision of approximately EUR 210 million. These historical amounts do not establish current subsidiary value or earnings. DiA’s 2023 acquisition is corroborated by transaction counsel and subsequent subsidiary disclosure, but final consideration was not established.^{2, 20, 21, 22}

The March 2026 Budapest notice provides product-specific manufacturing evidence: the ministry described the proposed spectral CT scanner as developed in Haifa and manufactured entirely in Israel. This does not establish the origin of every Philips scanner. Its proposed USD 1.5 million purchase from Philips Israel remains distinct from verified payment or delivery.⁸

Further notices concern proposed servicing. Rambam’s December 2025 notice specified NIS 3,990,428 for mixed equipment categories, including Philips systems, through Medtechnica. Sourasky’s December 2025 notice proposed USD 112,100 including VAT for 36 months of ICT 85003 servicing through Philips Israel. Neither establishes execution or final Philips receipts.^{25, 26}

Counter-Arguments and Evidence Limits

The strongest defence is that the identified operations manufacture and support civilian medical technology. No public evidence identified of a Philips settlement factory, office or verified sale to a named settlement institution. The audits also found no verified direct Israeli military supply contract or quantified settlement revenue. Ownership of Israeli healthcare operations does not itself establish those separate allegations.^{1, 2, 18, 23, 24}

Financial precision is limited. No public evidence identified of verified Israel-only consolidated revenue, quantified Israeli tax payments or annual profit repatriation. Research-programme listings do not establish amounts actually disbursed. The subsidiary schedule establishes ownership, not dividend, royalty or transfer-pricing flows.^{2, 3, 13}

Shareholder activity remains separate. Exor’s PhaseV investment is independently documented, while DustPhotonics was acquired by Credo in May 2026; the audit does not establish Exor’s individual proceeds or residual indirect exposure. Ora describes itself as an independent venture-portfolio manager, not an Exor-controlled operating subsidiary. These facts cannot be converted into Philips investments through association.^{39, 42, 43, 44}

Named Entities and Evidence Map

Political: Political

Mechanism of Involvement

The clearest promotional association is MIXiii. Official materials retrospectively identify Philips as a silver sponsor of the March 2025 conference. The event was organised by IATI, a nonprofit industry association promoting Israeli technology and international commercial engagement. Government institutions appeared in separately labelled cooperation, partnership and support categories.^{4, 5, 6}

This establishes public sponsorship recognition within an initiative connected to state-associated economic development. It does not identify a government body as the direct recipient of Philips’ contribution. IATI reported more than 1,700 participants from 32 countries; no Philips-specific effect on attendance, investment or political attitudes was established.^{4, 5, 6}

The 2026 catalogue separately includes a Philips profile. That supports further commercial participation, but not a verified 2026 silver sponsorship, financial amount or binding commitment into 2027. Sponsorship continuity remains unresolved.^{7, 34}

The Budapest scanner proposal supplies a second mechanism: an identified Philips subsidiary was the proposed supplier in a state initiative expressly intended to demonstrate Israeli medical innovation and generate favourable attention in Hungary. The ministry also described humanitarian value. Execution and Philips’ formulation or endorsement of the ministry’s public-diplomacy aims were not established.⁸

Counter-Arguments and Evidence Limits

Philips’ strongest defence is ordinary healthcare commerce and industry participation. Sponsorship recognition is not evidence of payments to a political party, military organisation or settlement authority. The sponsorship’s legal recipient, consideration and form - cash, services or another arrangement - were not established. The Budapest initiative concerned a children’s hospital and remained a proposed procurement.^{8, 4, 5, 6}

No public evidence identified of Philips endorsing Israeli military operations or settlement expansion, lobbying for annexation or anti-BDS measures, or making verified donations to the IDF or settlement organisations. The audits likewise did not establish an Israeli state controlling interest or a corporate charter requiring support for Israeli policy.^{45, 46, 47}

The communications comparison is bounded. Philips publicised humanitarian assistance to Ukraine, while the political audit identified no comparable post-October 2023 corporate announcement specifically assisting Palestinian civilian healthcare. This is an absence in reviewed communications, not proof that no assistance occurred or that silence establishes endorsement. Philips’ Palestinian distributor listings provide additional evidence against treating its healthcare presence as exclusively Israeli.^{18, 45, 32, 29}

The audits did not independently verify Philips as a UN settlement-database enterprise or establish it as an expressly named BDS Movement priority target. The dossier’s scoring category should not be represented as either designation.^{45, 48}

Named Entities and Evidence Map

Complicity Index Score

Method: V6.6. Final human-vetted values.

• V_MAX: 9.00 Avg_OTHERS: 2.50
• BRS Score: 792 Tier: B (Severe Complicity)

The economic maximum reflects controlled subsidiaries, continuing manufacturing, acquisitions and research activity; the political value rests on documented industry sponsorship and state-associated promotional procurement, subject to the limits above.^{1, 2, 3, 8, 4} Together these explain the supplied BRS 792 / Tier B classification, while the military and digital scores remain zero. The method is scale-free, evidence-only and human-vetted; these fixed values are reproduced without recalculation or unsupported reconstruction of numeric thresholds.

Methodology Note

• Evidence boundary: This dossier compiles the four supplied domain audits, using their source records and preserving unresolved, proposed and unverified classifications.
• Scale-free assessment: Impact (I) concerns activity type; Magnitude (M) concerns scale; Proximity (P) concerns directness. Company size alone does not establish involvement.
• Temporal rule: Historical transactions are dated; divested, exited or acquired-away operations are mitigated. Proposed engagement dates do not establish execution or continuing performance.
• Entity attribution: No transitive guilt. Parent subsidiaries, distributors, shareholders, portfolio companies and independent managers require distinct evidence of ownership, conduct or direction.
• Settlement rule: Verified settlement operations dual-count in Economic and Political. No such Philips operation was established by the supplied audits.
• Negative findings: “No public evidence identified” reports the outcome of the audits’ checks, not universal proof of absence. Procurement intentions, contractual permissions and company statements are not treated as completed performance or independently verified compliance.